We examined the long-term effects of everolimus in patients with renal angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis.Following favorable results from the double-blind core phase of EXIST-2 (NCT00790400), patients were allowed to receive open-label everolimus (extension phase). Patients initially randomly assigned to everolimus continued on the same dose; those who were receiving placebo crossed over to everolimus 10 mg/day. Dose modifications were based on tolerability. The primary end point was angiomyolipoma response rate, defined as a ≥50% reduction from baseline in the sum volume of target renal angiomyolipomas in the absence of new target angiomyolipomas, kidney volume increase of >20% f...
Abstract Background Tuberous sclerosis complex (TSC) is a rare autosomal dominant genetic disorder c...
Background: Renal angiomyolipomas (AML) are usual manifestations of tuberous sclerosis complex (TSC)...
Abstract Background Tuberous sclerosis complex is an autosomal dominant genetic disorder that affect...
Objectives We examined the long-term effects of everolimus in patients with renal angiomyolipoma ass...
Objectives We examined the long-term effects of everolimus in patients with renal angiomyolipoma ass...
Renal angiomyolipomas (AML) are usual manifestations of tuberous sclerosis complex (TSC) that may ca...
Renal angiomyolipomas (AML) are usual manifestations of tuberous sclerosis complex (TSC) that may ca...
IntroductionThe EXIST-2 (NCT00790400) study demonstrated the superiority of everolimus over placebo ...
<div><p>Background</p><p>Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, has demonstra...
BACKGROUND: Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, has demonstrated efficacy ...
INTRODUCTION:The EXIST-2 (NCT00790400) study demonstrated the superiority of everolimus over placebo...
We evaluated the efficacy of everolimus in 3 patients who had huge renal angiomyolipomas associated ...
The past year has seen two important milestones in the experience with everolimus reveals uniform re...
Abstract Background Tuberous sclerosis complex (TSC) is a rare autosomal dominant genetic disorder c...
Background: Renal angiomyolipomas (AML) are usual manifestations of tuberous sclerosis complex (TSC)...
Abstract Background Tuberous sclerosis complex is an autosomal dominant genetic disorder that affect...
Objectives We examined the long-term effects of everolimus in patients with renal angiomyolipoma ass...
Objectives We examined the long-term effects of everolimus in patients with renal angiomyolipoma ass...
Renal angiomyolipomas (AML) are usual manifestations of tuberous sclerosis complex (TSC) that may ca...
Renal angiomyolipomas (AML) are usual manifestations of tuberous sclerosis complex (TSC) that may ca...
IntroductionThe EXIST-2 (NCT00790400) study demonstrated the superiority of everolimus over placebo ...
<div><p>Background</p><p>Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, has demonstra...
BACKGROUND: Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, has demonstrated efficacy ...
INTRODUCTION:The EXIST-2 (NCT00790400) study demonstrated the superiority of everolimus over placebo...
We evaluated the efficacy of everolimus in 3 patients who had huge renal angiomyolipomas associated ...
The past year has seen two important milestones in the experience with everolimus reveals uniform re...
Abstract Background Tuberous sclerosis complex (TSC) is a rare autosomal dominant genetic disorder c...
Background: Renal angiomyolipomas (AML) are usual manifestations of tuberous sclerosis complex (TSC)...
Abstract Background Tuberous sclerosis complex is an autosomal dominant genetic disorder that affect...